Semantic Scholar uses AI to extract papers important to this topic.
Peroral administration of tacrine, the first acetylcholinestearse inhibitor licensed for the treatment of Alzheimer's disease, is… Expand OBJECTIVES
To determine the effects of cholinesterase inhibition with tacrine hydrochloride for the symptoms of Alzheimer disease… Expand OBJECTIVE
To examine the effects of tacrine hydrochloride in patients with Alzheimer disease (AD) and detectable baseline… Expand Objective. —To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30 weeks in patients with probable… Expand OBJECTIVE
To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30 weeks in patients with probable… Expand To assess the value of serum measurements of tacrine hydrochloride and its metabolite in predicting risk of adverse reaction in… Expand OBJECTIVE
To compare efficacy and safety of tacrine hydrochloride with placebo in patients with probable Alzheimer's disease… Expand BACKGROUND
In Alzheimer's disease, there is a marked decline in the function of cholinergic neurons in the brain. However… Expand The clinical pharmacokinetics of tacrine hydrochloride have been characterized in patients who have Alzheimer's disease. Serum… Expand